A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma
Annals of Oncology, 08/21/2012
Morschhauser F et al. – Rituximab induced a high rate of durable complete responses (CRs) in patients with clinically detectable disease, as well as durable eradication of PCR–detectable disease in patients with follicular lymphoma (FL) after autologous stem–cell transplantation (ASCT). Continued molecular responses assessed with a highly sensitive and clono–specific PCR technique were correlated with an excellent disease control.